A bitter management shake-up. Angry public outbursts. A “narcissistic” pastor whose word is gospel. What in God’s name is ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed ...

Stocks recently featured in the blog include Merck MRK and AbbVie ABBV. Here are highlights from Tuesday’s Analyst Blog: Merck and AbbVie are leading pharmaceutical companies with strong ...

Cyprumed may receive up to $493 million in milestone payments from Merck for peptide drug delivery tech. Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist.

RAHWAY, N.J., April 14, 2025 /PRNewswire/ -- The Merck Manuals is pleased to announce its collaboration with Microsoft to integrate its esteemed professional medical reference into healthcare ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

“Large pharma is going to be very skittish about anhedonia,” says Potter, a consultant and former drug developer at the National Institute of Mental Health (NIMH), Lilly and Merck & Co. The ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other ...

What is the current and next Honkai Star Rail banner? If you want to pick up the best five-star characters for your team, then wishing on banners is your best bet. HSR banners rotate regularly ...

What is the current and next Wuthering Waves banner? Otherwise known as Convenes, WuWa banners run on a three-week rotation, which doesn’t give you much time to decide which characters to pull ...

Lobbying firms have continued to hoover up new business from colleges and universities as the White House escalates its war with higher education.